Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.
Compare the efficacy and safety of viramidine 600 mg twice a day (BID) versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a to treatment-naive patients with chronic hepatitis C (CHC)
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90033, United States
Annadale, Virginia 22003, United States
Buenos Aires, Buenos Aires (C1199ACK), Argentina
Buenos Aires, Buenos Aires (C1264AAA), Argentina
Buenos Aires, Buenos Aires (C1280AEB), Argentina
Vandouevre Les Nancy, 54511, France
Tel Aviv, 64239, Israel
Krakow, 31-531, Poland
Saint Petersburg, 193163, Russia